EpiVax announces laboratory expansion and optimized NAM-focused in vitro services
Summary
EpiVax expanded its Providence lab space to more than double its capacity for advanced immunology testing. The company is positioning its NAM-based in vitro services as a stronger option for therapeutic developers that need human-relevant immunogenicity risk assessment. It combines in-silico tools with modular in-vitro assays to support development programs across biologics, peptides, biosimilars, and new therapy modalities. The expansion should help EpiVax handle more partner projects and support more regulatory submissions. The company says the investment will improve workflow efficiency, consistency, and collaboration for its clients.
Classifications
industries
Pharmaceuticals and Chemical
applications
Accounting and Taxes
AskAI Classifications
Labels
Bioinformatics Software
SaaS
Developer Tools
Linked Companies
EpiVax
$1M to $5M